Increased XPO1 levels have been observed in a variety of malignancies including CD138+ PCs from patients with active MM and are associated with poor survival outcomes, making XPO1 an attractive molecular target for novel therapies [251]. This evidence concerns the gene XPO1 and Miyoshi myopathy.